Cargando…

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma

PURPOSE: Intratumoral interleukin-2 (IL-2) is effective but does not generate systemic immunity. Intravenous ipilimumab produces durable clinical response in a minority of patients, with potentially severe toxicities. Circulating anti-tumor T cells activated by ipilimumab may differ greatly from tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Abhijit, Williams, Matthew A., Meek, Stephanie M., Bowen, Randy C., Grossmann, Kenneth F., Andtbacka, Robert H.I., Bowles, Tawnya L., Hyngstrom, John R., Leachman, Sancy A., Grossman, Douglas, Bowen, Glen M., Holmen, Sheri L., VanBrocklin, Matthew W., Suneja, Gita, Khong, Hung T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325451/
https://www.ncbi.nlm.nih.gov/pubmed/27391442
http://dx.doi.org/10.18632/oncotarget.10453

Ejemplares similares